Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine PR in myotonic dystrophy type 1 and type 2
NCT06549400Phase 3Enrolling by invitation
- Sponsor
- Lupin Limited
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 3 trial of mexiletine in myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2), sponsored by Lupin Limited. Started Sep 2025; status: enrolling by invitation.
02
Drugs
mexiletine
03
Conditions
myotonic dystrophy type 1 (DM1)myotonic dystrophy type 2 (DM2)
Beyond the preview
Go deeper on NCT06549400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549400.